Jul 2018 $3 M No. 10 $2 to $10 million 3
Fibrocell Science, Inc.: Raise no. 10, Jul 2018 × Investors in this round 3 investors had bought by the notice of Jul 17, 2018: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $8,384
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice John M. Maslowski · Executive Officer, Director · President and Chief Executive Officer Christine E. St.Clare · Director Douglas J. Swirsky · Director · Chairman of the Board Julian P. Kirk · Director Kelvin D. Moore · Director Marc B. Mazur · Director Marcus E. Smith · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co., LLC (CRD 375) · New York, New York Sold in FL, IL, NJ, TX, and outside the US Remarks in the notice On fees: “H.C. Wainwright received the above sales commissions in connection with the private placement of warrants. It also received the HCW Warrants in connection with a registered direct offering by the Company.”On the amounts: “"The warrants and underlying shares of common stock include warrants (i) to purchase 958,152 shares of common stock issued to certain institutional investors and (ii) to purchase 103,186 shares of common stock issued to H.C. Wainwright (""HCW Warrants"")"”Signed by John M. Maslowski, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 17, 2018. Read the notice at the SEC .
options SEC May 2018 $5 M No. 9 $2 to $10 million 4
Fibrocell Science, Inc.: Raise no. 9, May 2018 × Investors in this round 4 investors had bought by the notice of Jun 13, 2018: 4 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $13,376
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice John M. Maslowski · Executive Officer, Director · President and Chief Executive Officer Christine E. St.Clare · Director Douglas J. Swirsky · Director · Chairman of the Board Julian P. Kirk · Director Kelvin D. Moore · Director Marc B. Mazur · Director Marcus E. Smith · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co., LLC (CRD 375) · New York, New York Sold in CA, IL, NJ, NY, and outside the US Remarks in the notice On fees: “H.C. Wainwright received the above sales commissions in connection with the private placement of warrants. It also received the HCW Warrants in connection with a registered direct offering by the Company.”On the amounts: “"The warrants and underlying shares of common stock include warrants (i) to purchase 1,528,668 shares of common stock issued to certain institutional investors and (ii) to purchase 142,676 shares of common stock issued to H.C. Wainwright (""HCW Warrants"")"”Signed by John M. Maslowski, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 13, 2018. Read the notice at the SEC .
options SEC Aug 2016 $18 M No. 8 $10 to $50 million 14
Fibrocell Science, Inc.: Raise no. 8, Aug 2016 × Investors in this round 14 investors had bought by the notice of Aug 24, 2016: 14 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $18 M of $25 M offered; $7 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities Exemption claimed Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David Pernock · Executive Officer, Director · Chairman of the Board and Chief Executive Officer John F. Maslowski · Executive Officer · Senior Vice President, Scientific Affairs Keith A. Goldan · Executive Officer · Senior Vice President, Chief Financial Officer and Treasurer Michael F. Marino · Executive Officer · Senior Vice President, General Counsel and Corporate Secretary Christine E. St.Clare · Director Douglas J. Swirsky · Director Julian F. Kirk · Director Kelvin F. Moore · Director Marc F. Mazur · Director Marcus E. Smith · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Michael F. Marino, Senior VP, General Counsel and Corporate Sec.. Source: SEC Form D, newest notice filed Aug 24, 2016. Read the notice at the SEC .
debt, options SEC Oct 2012 $45 M No. 7 $10 to $50 million 114
Fibrocell Science, Inc.: Raise no. 7, Oct 2012 × Investors in this round 114 investors had bought by the notice of Oct 15, 2012: 114 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $45 M of $45 M offered
Smallest investment taken $1,500
What was sold equity
Meant to last a year or less
Issuer's revenue Up to $1 million
Sales commissions $2,700,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David Pernock · Executive Officer, Director Declan Daly · Executive Officer, Director Julian Kirk · Director Kelvin Moore · Director Marc Mazur · Director Marcus Smith · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round John Carris Investments LLC (CRD 145767) · New York, New York Sold in all US states, and outside the US Barclays (CRD 19714) · New York, New York Sold in MA, NJ, NY, TX, VT MTS Securities, LLC (CRD 104059) · New York, New York Sold in CA, CT, IL, MA, NY, VA Signed by David Pernock, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 15, 2012. Read the notice at the SEC .
equity SEC May 2012 $3 M No. 6 $2 to $10 million 63
Fibrocell Science, Inc.: Raise no. 6, May 2012 × Investors in this round 63 investors had bought by the notice of May 18, 2012: 63 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $12 M offered; $9 M still to sell
Smallest investment taken $10,000
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue Up to $1 million
Sales commissions $1,200,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice David Pernock · Executive Officer, Director Declan Daly · Executive Officer, Director George J. Korkos · Director Kelvin J. Moore · Director Marc Mazur · Director Robert Langer · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round John Thomas Financial Inc. (CRD 40982) · New York, New York Sold in all US states, and outside the US John Carris Investments LLC (CRD 145767) · New York, New York Sold in all US states, and outside the US Remarks in the notice On fees: “Assumes sale of total offering amount. Excludes (i) 3% expense allowance and (ii) warrants to purchase shares of common stock.”On the amounts: “Total Offering Amount includes $3,000,000 over-subscription amount.”Signed by David Pernock, Chief Executive Officer. Source: SEC Form D, newest notice filed May 18, 2012. Read the notice at the SEC .
equity, options SEC Aug 2011 $23 M No. 5 $10 to $50 million 75
Fibrocell Science, Inc.: Raise no. 5, Aug 2011 × Investors in this round 75 investors had bought by the notice of Aug 18, 2011: 75 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $23 M of $23 M offered
Smallest investment taken $10,000
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Up to $1 million
Sales commissions $1,595,664
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David Pernock · Executive Officer, Director Declan Daly · Executive Officer, Director George J. Korkos · Director Kelvin Moore · Director Marc Mazur · Director Robert Langer · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Gleacher & Company Securities, Inc. (CRD 298) · New York, New York Sold in all US states, and outside the US John Carris Investments (CRD 145767) · New York, New York Sold in all US states, and outside the US Rodman & Renshaw, LLC (CRD 16415) · New York, New York Sold in all US states, and outside the US Remarks in the notice On fees: “The placement agents will be issued five-year warrants to purchase a number of shares of common stock equal to 3% of the gross proceeds of the offering divided by the trailing volume weighted average price for the five days proceeding the closing date.”Signed by David Pernock, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 18, 2011. Read the notice at the SEC .
equity, options SEC Dec 2010 $4 M No. 4 $2 to $10 million 67
Fibrocell Science, Inc.: Raise no. 4, Dec 2010 × Investors in this round 67 investors had bought by the notice of Feb 3, 2011: 67 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $8 M offered; $4 M still to sell
Smallest investment taken $5,000
What was sold options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Up to $1 million
Sales commissions $343,440
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David Pernock · Executive Officer, Director Declan Daly · Executive Officer, Director George J. Korkos · Director Kelvin Moore · Director Marc Mazur · Director Robert Langer · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round John Carris Investments LLC (CRD 145767) · broker-dealer John Carris Investments LLC (CRD 145767) · New York, New York Sold in all US states, and outside the US Signed by Declan Daly, Chief Financial Officer, Chief Operating Officer& Controller. Source: SEC Form D, newest notice filed Feb 3, 2011. Read the notice at the SEC .
options SEC Jul 2010 $3 M No. 3 $2 to $10 million 20
Fibrocell Science, Inc.: Raise no. 3, Jul 2010 × Investors in this round 20 investors had bought by the notice of Aug 4, 2010: 20 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken $15,000
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions $216,160
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David Pernock · Executive Officer, Director Declan Daly · Executive Officer, Director George Korkos · Director Kelvin Moore · Director Marc Mazur · Director Paul Hopper · Director Robert Langer · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Viriathus Capital · broker-dealer John Carris Investments LLC (CRD 145767) · New York, New York Sold in AZ, CA, CT, FL, IL, LA, NJ, NY, VA John Carris Investments LLC (CRD 145767) · New York, New York Sold in AZ, CA, CT, FL, IL, LA, NJ, NY, VA Remarks in the notice On fees: “$216,160 in cash plus Warrants to purchase 360,267 shares of Common Stock at $0.60 per share”Signed by Declan Daly, Cfo. Source: SEC Form D, newest notice filed Aug 4, 2010. Read the notice at the SEC .
equity, options SEC Mar 2010 $4 M No. 2 $2 to $10 million 23
Fibrocell Science, Inc.: Raise no. 2, Mar 2010 × Investors in this round 23 investors had bought by the notice of Mar 29, 2010: 23 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken $4,575
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions $304,600
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David Pernock · Executive Officer, Director Declan Daly · Executive Officer, Director Kelvin Moore · Director Paul Hopper · Director Robert Langer · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round John Carris Investments LLC (CRD 145767) · New York, Ny Sold in no state named Viriathus Capital · broker-dealer John Carris Investments LLC (CRD 145767) · New York, Ny Sold in no state named Remarks in the notice On fees: “$304,600 in cash plus Warrants to purchase 406,133 shares of Common Stock at $0.75 per share”Signed by Declan Daly, Cfo. Source: SEC Form D, newest notice filed Mar 29, 2010. Read the notice at the SEC .
equity, options SEC Oct 2009 $5 M No. 1 $2 to $10 million 11
Fibrocell Science, Inc.: Raise no. 1, Oct 2009 × Investors in this round 11 investors had bought by the notice of Mar 29, 2010: 11 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken $50,000
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions $325,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Declan Daly · Executive Officer, Director David Pernock · Director Kelvin Moore · Director Paul Hopper · Director Robert Langor · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Viriathus Capital · broker-dealer John Carris Investments LLC (CRD 145767) · New York, Ny Sold in no state named John Carris Investments LLC (CRD 145767) · New York, Ny Sold in no state named Remarks in the notice On fees: “$325,000 in cash plus Warrants to purchase 250,000 shares at $1.30 share”Signed by Declan Daly, Ceo. Source: SEC Form D, newest notice filed Mar 29, 2010. Read the notice at the SEC .
equity, options SEC